Working... Menu

A Study of IDN-6556 in Subjects With Liver Cirrhosis (LC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02230670
Recruitment Status : Completed
First Posted : September 3, 2014
Results First Posted : July 5, 2017
Last Update Posted : July 5, 2017
Information provided by (Responsible Party):
Conatus Pharmaceuticals Inc.

Brief Summary:
This is a multicenter study to see if treatment with IDN-6556 can help improve the liver function of patients with liver cirrhosis with Model for End-Stage Liver Disease scores between 11-18.

Condition or disease Intervention/treatment Phase
Liver Cirrhosis Hepatic Cirrhosis Drug: IDN-6556 Drug: Placebo Phase 2

Detailed Description:
Numerous studies have shown that caspase cleaved cytokeratin 18 (cCK18) is elevated in the serum of liver disease patients and has been associated with disease severity, thus associating both excessive apoptosis and caspase activity with disease. Studies have also shown that caspase cleaved cytokeratin 18 is generally elevated to an even greater degree in cirrhosis than in other liver diseases. In addition, increasing stages of cirrhosis from Child-Pugh A, Child-Pugh B to Child-Pugh C are associated with progressively higher levels of caspase cleaved cytokeratin 18. Therefore, it appears that apoptosis and caspase activity tend to correlate with the stage of cirrhosis. A caspase inhibitor like IDN-6556 could have clinical utility by reducing the rate of apoptosis in cirrhotic patients and potentially reduce the progression of disease as determined by clinical markers of progression.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 87 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis
Study Start Date : August 2014
Actual Primary Completion Date : January 2016
Actual Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis

Arm Intervention/treatment
Experimental: IDN-6556
25 mg BID of IDN-6556
Drug: IDN-6556
25 mg BID
Other Names:
  • emricasan
  • PF-03491390

Placebo Comparator: Placebo
Placebo BID
Drug: Placebo

Primary Outcome Measures :
  1. Change From Baseline at Month 3 in cCK18/M30 [ Time Frame: 3 months ]
    Baseline, Month 3, and change between for cCK18/M30

  2. Change From Baseline at Month 3 in cCK18/M30 [ Time Frame: 3 months ]
    Data was log-transformed for analysis purposes

Secondary Outcome Measures :
  1. Change From Baseline to Month 3 in MELD Score [ Time Frame: 3 Months ]

    The Model for End-Stage Liver Disease (MELD) is a scoring system for assessing the severity of chronic liver disease and uses the subject's values for total bilirubin, serum creatinine, and the international normalized ratio (INR) for prothrombin time to predict survival. MELD is calculated according to the following formula:

    MELD = 3.78×ln[serum bilirubin (mg/dL)] + 11.2×ln[INR] + 9.57×ln[serum creatinine (mg/dL)] + 6.43

    MELD scores are reported as whole numbers, so the result of the equation above is rounded. Notes: If the patient has been dialyzed twice within the last 7 days, then the value for serum creatinine used should be 4.0. Any value less than one is given a value of 1 (i.e. if bilirubin is 0.8, a value of 1.0 is used) to prevent the occurrence of scores below 0 (the natural logarithm of 1 is 0, and any value below 1 would yield a negative result). The higher the MELD score the more severe the disease state.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subjects of minimum adult legal age (according to local laws for signing the informed consent document), able to provide written informed consent, and able to understand and willing to comply with the requirements of the study
  • Clinical, radiological, or biochemical evidence of liver cirrhosis
  • Model for End-Stage Liver Disease (MELD) Score of 11 to 18 during the Screening period
  • Willingness to utilize two reliable forms of contraception (for both males and females of childbearing potential) from Screening to one month after the last dose of study drug.

Exclusion Criteria:

  • Known infection with human immunodeficiency virus (HIV)
  • Auto-immune hepatitis
  • Subjects with evidence of uncontrolled infection, defined as persistent bacterial culture positivity despite adequate antibiotic therapy
  • HCV infected subjects who are receiving or plan to receive anti-viral therapy during the study
  • Untreated esophageal varices with high risk stigmata for hemorrhage
  • Variceal hemorrhage within 3 months of Screening
  • Ascites not adequately controlled on stable background medication
  • Other non-liver organ failure
  • Child-Pugh score of 10-15 (Child-Pugh C classification)
  • Use of vasoactive drugs (at or within 3 months of Screening) that may impair hepatic blood flow
  • Change in dose or regimen within 3 months of Screening of:

    1. Fibrates or statins
    2. Angiotensin II receptor antagonist or angiotensin converting enzyme (ACE) inhibitor
  • Use of chronic anticoagulation therapy including but not limited to Vitamin K/Factor Xa antagonists/inhibitors
  • Use of the following drugs within 2 months of Screening:

    1. Systemic corticosteroids
    2. Known or suspected use of illicit drugs or drugs of abuse (allowed if medically prescribed or indicated)
  • Concomitant pancreatitis
  • Active inflammatory bowel disease
  • Diagnosed or suspected systemic lupus erythematosus (SLE) and/or rheumatoid arthritis (RA)
  • Subjects with active or history of malignancies other than hepatocellular carcinoma (HCC) within Milan criteria or curatively treated skin cancer (basal cell or squamous cell carcinomas), unless adequately treated or in complete remission for five or more years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02230670

  Show 28 Study Locations
Sponsors and Collaborators
Conatus Pharmaceuticals Inc.
Layout table for investigator information
Study Chair: Dave Hagerty, MD Conatus Pharmaceuticals

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Conatus Pharmaceuticals Inc. Identifier: NCT02230670     History of Changes
Other Study ID Numbers: IDN-6556-10
First Posted: September 3, 2014    Key Record Dates
Results First Posted: July 5, 2017
Last Update Posted: July 5, 2017
Last Verified: June 2017

Keywords provided by Conatus Pharmaceuticals Inc.:
Liver Cirrhosis
Hepatic Cirrhosis

Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Cirrhosis
Pathologic Processes
Liver Diseases
Digestive System Diseases